These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates. Di L; Kerns EH; Hong Y; Kleintop TA; McConnell OJ; Huryn DM J Biomol Screen; 2003 Aug; 8(4):453-62. PubMed ID: 14567798 [TBL] [Abstract][Full Text] [Related]
3. A high throughput metabolic stability screening workflow with automated assessment of data quality in pharmaceutical industry. Xu R; Manuel M; Cramlett J; Kassel DB J Chromatogr A; 2010 Mar; 1217(10):1616-25. PubMed ID: 20132940 [TBL] [Abstract][Full Text] [Related]
4. High throughput microsomal stability assay for insoluble compounds. Di L; Kerns EH; Li SQ; Petusky SL Int J Pharm; 2006 Jul; 317(1):54-60. PubMed ID: 16621364 [TBL] [Abstract][Full Text] [Related]
5. Simple strategies for reducing sample loads in in vitro metabolic stability high-throughput screening experiments: a comparison between traditional, two-time-point and pooled sample analyses. Zhao SX; Forman D; Wallace N; Smith BJ; Meyer D; Kazolias D; Gao F; Soglia J; Cole M; Nettleton D J Pharm Sci; 2005 Jan; 94(1):38-45. PubMed ID: 15761928 [TBL] [Abstract][Full Text] [Related]
6. [Rapid pharmacokinetics screening of drug candidates in vitro and in vivo]. Dong XN; Zhu XX; Meng ZY; Liu JL; Cao YL; Dou GF Yao Xue Xue Bao; 2009 Nov; 44(11):1309-12. PubMed ID: 21355332 [TBL] [Abstract][Full Text] [Related]
7. Moderate correlations of in vitro versus in vivo pharmacokinetics questioning the need of early microsomal stability testing. Schrezenmeier E; Zollmann FS; Seidel K; Böhm C; Schmerbach K; Kroh M; Kirsch S; Klare S; Bernhard S; Kappert K; Goldin-Lang P; Skuballa W; Unger T; Funke-Kaiser H Pharmacology; 2012; 90(5-6):307-15. PubMed ID: 23037500 [TBL] [Abstract][Full Text] [Related]
8. An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. McNaney CA; Drexler DM; Hnatyshyn SY; Zvyaga TA; Knipe JO; Belcastro JV; Sanders M Assay Drug Dev Technol; 2008 Feb; 6(1):121-9. PubMed ID: 18336089 [TBL] [Abstract][Full Text] [Related]
9. Supercritical fluid chromatography/tandem mass spectrometric method for analysis of pharmaceutical compounds in metabolic stability samples. Hsieh Y; Favreau L; Schwerdt J; Cheng KC J Pharm Biomed Anal; 2006 Feb; 40(3):799-804. PubMed ID: 16095863 [TBL] [Abstract][Full Text] [Related]
10. Applications of high throughput microsomal stability assay in drug discovery. Di L; Kerns EH; Ma XJ; Huang Y; Carter GT Comb Chem High Throughput Screen; 2008 Jul; 11(6):469-76. PubMed ID: 18673274 [TBL] [Abstract][Full Text] [Related]
11. Direct determination of the ratio of unbound fraction in plasma to unbound fraction in microsomal system (fu p/fu mic) for refined prediction of phase I mediated metabolic hepatic clearance. Deshmukh SV; Harsch A J Pharmacol Toxicol Methods; 2011; 63(1):35-9. PubMed ID: 20433934 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice. Smith NF; Hayes A; Nutley BP; Raynaud FI; Workman P Cancer Chemother Pharmacol; 2004 Dec; 54(6):475-86. PubMed ID: 15526201 [TBL] [Abstract][Full Text] [Related]
13. Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models. Siramshetty VB; Shah P; Kerns E; Nguyen K; Yu KR; Kabir M; Williams J; Neyra J; Southall N; Nguyễn ÐT; Xu X Sci Rep; 2020 Nov; 10(1):20713. PubMed ID: 33244000 [TBL] [Abstract][Full Text] [Related]
14. Interstrain differences of in vitro metabolic stability and impact on early drug discovery. Richmond W; Wogan M; Isbell J; Gordon WP J Pharm Sci; 2010 Nov; 99(11):4463-8. PubMed ID: 20845445 [TBL] [Abstract][Full Text] [Related]
15. A novel incubation direct injection LC/MS/MS technique for in vitro drug metabolism screening studies involving the CYP 2D6 and the CYP 3A4 isozymes. Bhoopathy S; Xin B; Unger SE; Karnes HT J Pharm Biomed Anal; 2005 Apr; 37(4):739-49. PubMed ID: 15797796 [TBL] [Abstract][Full Text] [Related]
16. Efficiency in Drug Discovery: Liver S9 Fraction Assay As a Screen for Metabolic Stability. Richardson SJ; Bai A; Kulkarni AA; Moghaddam MF Drug Metab Lett; 2016; 10(2):83-90. PubMed ID: 26902079 [TBL] [Abstract][Full Text] [Related]
17. A novel approach to perform metabolite screening during the quantitative LC-MS/MS analyses of in vitro metabolic stability samples using a hybrid triple-quadrupole linear ion trap mass spectrometer. Shou WZ; Magis L; Li AC; Naidong W; Bryant MS J Mass Spectrom; 2005 Oct; 40(10):1347-56. PubMed ID: 16206149 [TBL] [Abstract][Full Text] [Related]
18. Rapid liquid chromatography with tandem mass spectrometry-based screening procedures for studies on the biotransformation of drug candidates. Fernández-Metzler CL; Owens KG; Baillie TA; King RC Drug Metab Dispos; 1999 Jan; 27(1):32-40. PubMed ID: 10068285 [TBL] [Abstract][Full Text] [Related]
19. In vitro drug metabolism using liver microsomes. Hill JR Curr Protoc Pharmacol; 2004 Feb; Chapter 7():Unit7.8. PubMed ID: 21956813 [TBL] [Abstract][Full Text] [Related]
20. Identification of a novel in vitro metabonate from liver microsomal incubations. Li C; Surapaneni S; Zeng Q; Marquez B; Chow D; Kumar G Drug Metab Dispos; 2006 Jun; 34(6):901-5. PubMed ID: 16554371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]